Biotech Industry · us
Viatris Plans $1.65 Billion Acquisition of Pacira to Expand Non-Opioid Pain Portfolio
Two marketed pain medicines, along with a gene therapy for knee osteoarthritis that has entered Phase 2 trials, will join Viatris’s portfolio. The deal adds a revenue base to its innovative medicines business while bringing development opportunities that still require clinical validation.
From acute pain after surgery to the long-term burden of knee osteoarthritis, non-opioid pain treatments are becoming an important focus for pharmaceutical companies expanding their portfolios. On October 8, Viatris announced that it had signed an agreement to acquire Pacira BioSciences, gaining two marketed medicines and its development pipeline to further expand its innovative medicines business.
The all-cash transaction values the acquisition at $36.50 per share, with a total equity value of approximately $1.65 billion. According to Reuters, the offer represents a 44.8% premium to Pacira’s closing share price on the previous trading day. Exparel and Zilretta generated net sales of $575.1 million and $116.6 million, respectively, in 2025, providing an established commercial base for the acquisition.
The two products address pain in different ways. Exparel encapsulates the local anesthetic bupivacaine in liposomes, allowing the drug to be released gradually for postoperative pain relief. Zilretta is an extended-release corticosteroid formulation injected into the joint for knee osteoarthritis pain. Both are non-opioid treatments, but each has distinct uses and mechanisms of action and cannot be regarded as interchangeable pain relief options.
The acquisition will also bring earlier-stage development assets. Pacira’s most advanced candidate, PCRX-201, is a locally administered gene therapy being developed for knee osteoarthritis and is currently in Phase 2 clinical development. The deal thus encompasses both established products and development risks. The acquisition announcement itself provided no new trial results and cannot serve as a basis for concluding that the therapy has demonstrated efficacy.
For Viatris, Pacira’s value also includes its commercial, medical affairs, and research and development capabilities in the United States. The company said it hopes to use its existing international network to expand the products into selected overseas markets and complement its fast-acting meloxicam portfolio. The acquisition is expected to be funded primarily with excess cash, with the remainder covered by short-term borrowing. Market expansion and integration benefits remain company expectations.
Documents Pacira filed with the U.S. Securities and Exchange Commission show that the tender offer must begin within 15 business days after the agreement is signed. Conditions for completing the transaction include reaching a majority-of-shares threshold and the expiration or termination of the applicable antitrust waiting period. After the tender offer is completed, a merger procedure requiring no separate shareholder vote will make Pacira a wholly owned subsidiary of Viatris. The two companies expect to complete the transaction by the end of 2026.
The deal allows Viatris to expand its pain treatment business with products that already generate sales revenue, but corporate expansion and clinical progress remain separate matters. Overseas launches and market access, post-acquisition integration, and subsequent evidence of the gene therapy’s efficacy and safety will all influence how far this strategy can go.